AUMED, a.s. completed a clinical trial, phase I, of the medicinal product TFI (Transfer Factor) lyophilized mucoadhesive tablet for buccal-oral administration on 18.11.2024. The new medicinal product is based on the results of AUMED’s own research activities in the field of transfer factors. The purpose of this study was to confirm that no significant safety issues would arise in a small sample of study subjects. No adverse effects were observed in this study. Other measurements, such as laboratory results, vital signs or physical findings, did not indicate any safety concerns that would require special attention.
Based on the submitted application and the supplied documents, the State Institute for Drug Control (Czech Republic) has authorized a…
AUMED, a.s. completed a clinical trial, phase I, of the medicinal product TFI (Transfer Factor) lyophilized mucoadhesive tablet for buccal-oral…
AUMED representatives participated in the 45th ICMM World Congress on Military Medicine held in Brisbane, Australia. At the congress, AUMED…
Research projects of Aumed, a.s. are financed by the European Structural Funds and with financial support from the state budget through the Ministry of Industry and Trade. A complete list of all ongoing and completed projects with this support can be found here.
Ministry of Industry and Trade
Program TRIO
European Union
European Regional Development Fund
OP Enterprise and Innovation for Competitiveness
Tel.: +420 603 587 701
Komořanská 326/63, 143 14 Praha - Modřany, Česká republika
(c) 2017, Aumed a.s
